M. Eileen Dolan
YOU?
Author Swipe
View article: Impact of Population Pharmacogenomics on Cisplatin‐Induced Neurotoxicities in Testicular Cancer Survivors
Impact of Population Pharmacogenomics on Cisplatin‐Induced Neurotoxicities in Testicular Cancer Survivors Open
Background Cisplatin is a commonly used chemotherapeutic across numerous cancer types that can cause neurotoxicities in patients, including peripheral sensory neuropathy, tinnitus, hearing loss, and vertigo. Objective We aimed to evaluate,…
View article: Complete mitochondrial genomes of <i>Notropis oxyrhynchus</i> and <i>Notropis buccula</i> (Cypriniformes: Leuciscidae)
Complete mitochondrial genomes of <i>Notropis oxyrhynchus</i> and <i>Notropis buccula</i> (Cypriniformes: Leuciscidae) Open
The Leuciscidae (minnows, shiners and relatives) is a diverse family of freshwater fishes with many species endangered due to anthropogenic stressors. Notropis oxyrhynchus and Notropis buccula are two shiners found only in the upper Brazos…
View article: 7542 Androgen Receptor Oligomerization State Allows Cells to Exhibit Non-Linear Dose Responses to Androgens Resulting in Distinct Biological Outputs
7542 Androgen Receptor Oligomerization State Allows Cells to Exhibit Non-Linear Dose Responses to Androgens Resulting in Distinct Biological Outputs Open
Disclosure: R. Safi: None. S.E. Wardell: None. P. Watkinson: None. X. Qin: None. M. Lee: None. S. Park: None. T. Krebs: None. E. Dolan: None. T. Tsuji: None. S. Nayak: None. M. Khater: None. M. Newlin: None. M. Kirkland: None. Y. Xie: None…
View article: Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy
Comprehensive Audiologic Analyses After Cisplatin-Based Chemotherapy Open
Importance Cisplatin is highly ototoxic but widely used. Evidence is lacking regarding cisplatin-related hearing loss (CRHL) in adult-onset cancer survivors with comprehensive audiologic assessments (eg, Words-in-Noise [WIN] tests, full-sp…
View article: Impact of pain and adverse health outcomes on long-term US testicular cancer survivors
Impact of pain and adverse health outcomes on long-term US testicular cancer survivors Open
Background No study has quantified the impact of pain and other adverse health outcomes on global physical and mental health in long-term US testicular cancer survivors or evaluated patient-reported functional impairment due to pain. Metho…
View article: Supplementary Fig. S4 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
Supplementary Fig. S4 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans Open
Supplementary Fig. S4 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
View article: Supplementary Figure 2 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
Supplementary Figure 2 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy Open
PDF file, 45KB, Putative binding sites for transcription factors in TUBB2A proximal promoter.
View article: Supplementary Table 2 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
Supplementary Table 2 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy Open
PDF file, 101KB, TUBB2A promoter variants in individuals high and low β-tubulin IIa mRNA expression.
View article: Supplementary Figures and Tables from Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer
Supplementary Figures and Tables from Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer Open
Supplementary Figures and Tables for Clinical and Genome Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer Figure S1. Diagram of Data Collection Pipeline. Table S1. EORTC-CIPN20 questionnaire. Figu…
View article: Data from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Data from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy Open
Purpose: Discovery of SNPs that predict a patient's risk of docetaxel-induced neuropathy would enable treatment individualization to maximize efficacy and avoid unnecessary toxicity. The objectives of this analysis were to discover SNPs as…
View article: Supplementary Table 3 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Supplementary Table 3 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy Open
Most Highly Enriched Canonical Pathways
View article: Data from Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy
Data from Clinical and Genome-Wide Analysis of Serum Platinum Levels after Cisplatin-Based Chemotherapy Open
Purpose:Serum platinum is measurable for years after completion of cisplatin-based chemotherapy (CBC). We report the largest investigation of serum platinum levels to date of 1,010 testicular cancer survivors (TCS) assessed 1–35 years afte…
View article: Supplementary Table S5 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Supplementary Table S5 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity Open
Proportion of variance in WFS1 expression explained by genetic effects in 11 relevant GTEx tissues.
View article: Supplementary Figure S3 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Supplementary Figure S3 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity Open
Robustness of the enrichment of top GWAS SNPs in Mendelian deafness genes.
View article: Supplemental Tables S1-6 from Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy
Supplemental Tables S1-6 from Pharmacoethnicity in Paclitaxel-Induced Sensory Peripheral Neuropathy Open
Supplemental Tables S1-6. Table S1. Clinical characteristics of cancer patients with paclitaxel-induced sensory peripheral neuropathy ({greater than or equal to} grade 2) as cases and no neuropathy as controls. Table S2. GWAS of SNPs locat…
View article: Data from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Data from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity Open
Purpose: Cisplatin is one of the most commonly used chemotherapy drugs worldwide and one of the most ototoxic. We sought to identify genetic variants that modulate cisplatin-associated ototoxicity (CAO).Experimental Design: We performed a …
View article: Supplementary Table 1 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
Supplementary Table 1 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy Open
PDF file, 52KB, Oligonucleotides used for β-tubulins mRNA quantification and TUBB2A sequencing and cloning.
View article: Supplementary Figure S4 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Supplementary Figure S4 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity Open
Top GWAS SNP rs62283056 is a cis-acting eQTL for WFS1 in several tissues.
View article: Supplementary Table S1 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Supplementary Table S1 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity Open
Demographic features and clinical characteristics of 511 genetically European male germ cell tumor (GCT) survivors at the time of audiometry.
View article: Supplementary Data from Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group
Supplementary Data from Genomic Variants of Cytarabine Sensitivity Associated with Treatment-Related Mortality in Pediatric AML: A Report from the Children's Oncology Group Open
Aim 1: SNPs included in analysis
View article: Supplementary Table S3 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Supplementary Table S3 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity Open
Top SNPs (P -5) in the meta-analysis of The Platinum Study and St. Jude cohorts.
View article: Supplementary Table 3 from Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients
Supplementary Table 3 from Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients Open
PDF - 76K
View article: Data from Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors
Data from Clinical and Genome-Wide Analysis of Multiple Severe Cisplatin-Induced Neurotoxicities in Adult-Onset Cancer Survivors Open
Purpose:Cisplatin is a first-line chemotherapeutic for many cancers, but causes neurotoxicity including hearing loss, tinnitus, and peripheral sensory neuropathy. However, no study has comprehensively characterized risk factors for develop…
View article: Supplementary Figure S1 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity
Supplementary Figure S1 from Variants in <i>WFS1</i> and Other Mendelian Deafness Genes Are Associated with Cisplatin-Associated Ototoxicity Open
Principal component analysis of The Platinum Study cohort.
View article: Supplementary Fig. S2 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
Supplementary Fig. S2 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans Open
Supplementary Fig. S2 from Genetic variants associated with carboplatin-induced cytotoxicity in cell lines derived from Africans
View article: Supplementary Figures 1-3 from Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients
Supplementary Figures 1-3 from Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients Open
PDF file - 263K
View article: Supplementary Figure 3: VAC14 Heterozygous Mice are Sensitive to Nociceptive Stimuli from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Supplementary Figure 3: VAC14 Heterozygous Mice are Sensitive to Nociceptive Stimuli from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy Open
Sensitivity to mechanical stimuli with Von Frey filaments for C57BL/6J mice and litter-mates heterozygous for VAC14 prior to docetaxel treatment. The figure displays the estimate of the proportion of mice without a hind-paw withdrawal resp…
View article: Supplementary Table 1 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Supplementary Table 1 from Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a <i>VAC14</i> Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy Open
Number of patients who experienced neuropathy, completed treatment without neuropathy and discontinued treatment early without having neuropathy while on study and within each range of cumulative treatment.
View article: Supplementary Figure 2 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy
Supplementary Figure 2 from Regulatory Polymorphisms in β-Tubulin IIa Are Associated with Paclitaxel-Induced Peripheral Neuropathy Open
PDF file, 45KB, Putative binding sites for transcription factors in TUBB2A proximal promoter.